One 100-mg IDHIFA® tablet once daily.
Swallow whole with water. Do not split or crush the tablets.
Take IDHIFA® tablets orally about the same time each day with or without food.
For patients without disease progression or unacceptable toxicity, treat for a minimum of 6 months to allow time for clinical response
|Adverse reaction||Recommended action|
|Noninfectious leukocytosis (WBC count greater than 30x109/L)|
|Elevation of bilirubin greater than 3x the ULN sustained for ≥2 weeks without elevated transaminases or other hepatic disorders|
ULN, upper limit of normal.
RECOMMENDATIONS FOR OTHER GRADE 3a OR HIGHER TOXICITY CONSIDERED RELATED TO TREATMENT, INCLUDING TLS
aGrade 1 is mild, Grade 2 is moderate, Grade 3 is serious, Grade 4 is life-threatening.
Patients must meet the following criteria to enroll:
Additional Terms and Conditions of the Celgene Commercial Co-pay Programs
© 2017 Celgene Corporation 06/17 US-CELG170216